IFX/AZA benefits outweigh risks in Crohn's disease, analysis finds

12/30/2011 | DoctorsLounge.com

Combined treatment with infliximab and azathioprine for one year appears to produce more benefits than risks among Crohn's disease patients, according to an analysis in Clinical Gastroenterology and Hepatology. Researchers found that the IFX/AZA combination was more effective than IFX monotherapy in treating the disease. The study was based on data from the Study of Biologic and Immunomodulator-Naive Patients With Crohn's Disease.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI